Financhill
Back

Ultragenyx Pharmaceutical 10K Form

Sell
17

RARE
Ultragenyx Pharmaceutical

Last Price:
$38.90
Seasonality Move:
11%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive RARE News And Ratings

See the #1 stock for the next 7 days that we like better than RARE

RARE Financial Statistics

Sales & Book Value

Annual Sales: $560.2M
Cash Flow: $-80.2M
Price / Cash Flow: 0
Annual Sales: $2.76
Price / Book: 13.76

Profitability

EPS (TTM): -6.34000
Net Income (TTM): $-569.2M
Gross Margin: $483.5M
Return on Equity: -194.36%
Return on Assets: -38.16%

Ultragenyx Pharmaceutical Earnings Forecast

Key Ultragenyx Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 20 years for RARE is 86.30%.
  • The Selling, General & Administrative Expenses for RARE have been equal to 57.41% of Gross Profit Margin.
  • The Research & Development expenses have been 124.57% of Revenue.
  • The Net Earning history of RARE is -101.60% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 8 years.

Ultragenyx Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RARE
CUSIP: 90400D
Website: ultragenyx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.37
Quick Ratio: 2.13

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RARE Technical Analysis vs Fundamental Analysis

Sell
17
Ultragenyx Pharmaceutical (RARE) is a Sell

Is Ultragenyx Pharmaceutical a Buy or a Sell?